Group 1 - The company held its second extraordinary general meeting on November 14, 2025, where it approved the cancellation of the supervisory board, increased the number of board seats, and revised the Articles of Association [2][13] - Wang Binchao was elected as the employee director of the third board of directors, with a term lasting until the end of the current board's term [2][5] - The board of directors now consists of 9 members, including 1 employee director, complying with relevant laws and regulations [2][3] Group 2 - The third board of directors' fourth meeting was held on November 14, 2025, where the adjustment of the audit committee members was approved [3][8] - The audit committee now includes Liu Shujin as the chairman, Xu Lin, and Wang Binchao [3][9] - The meeting was attended by all 9 directors, and the resolutions passed were deemed legal and effective [7][8] Group 3 - The company approved an investment of 323.2079 million yuan for the construction of a "High-Precision and Intelligent Pharmaceutical Industrialization Project" through its wholly-owned subsidiary [10] - The project is expected to be completed by April 2028 [10]

Core Points - The company FuYuan Pharmaceutical announced the election of Mr. Wang Binchao as the employee director of the third board of directors [2] Company Summary - FuYuan Pharmaceutical has made a significant governance change by electing a new employee director, which may reflect its commitment to employee representation in decision-making [2]

证券代码：601089 证券简称：福元医药 公告编号：临2025-078 北京福元医药股份有限公司 关于选举职工董事及调整审计委员会成员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、选举职工董事的情况 王斌超先生任公司职工董事后，公司董事中兼任高级管理人员以及由职工代表担 任的董事人数总计未超过公司董事总人数的二分之一，符合相关法律法规、规范性文 件及《公司章程》的规定。 二、董事会审计委员会成员调整情况 结合公司董事会成员变化情况，为进一步完善法人治理结构，结合公司实际情况， 公司于 2025 年 11 月 14 日召开第三届董事会第四次会议，审议通过《关于调整第三届 董事会审计委员会成员的议案》。会议以 9 票同意，0 票反对，0 票弃权通过该议案， 调整后的审计委员会成员为：刘书锦先生、徐麟先生、王斌超先生，刘书锦先生为主 任委员。 特此公告。 北京福元医药股份有限公司董事会 2025 年 11 月 15 日 附件：公司第三届董事会职工董事简历 王斌超先生，1979 年 3 月出生，中国国籍，无境外永久居留 ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-077 北京福元医药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 14 日 (二)股东大会召开的地点：公司会议室（北京市通州区漷县镇漷县南三街 8 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 188 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 350,744,168 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 74.9453 | 根据法律法规、规章和规范性文件对上市公司回购股份事宜的相关规定，上市公司回购专用 账户中的股份不享有股东会表决权，福元医药现有总股本 480,000,000 股，截至本次股东 会股权登记日，福元医药 ...

北京福元医药股份有限公司（以下简称"公司"）第三届董事会第四次会议于 2025 年 11 月 8 日以书面及邮件等方式发出会议通知，并于 2025 年 11 月 14 日在公司以现 场结合通讯表决的方式召开会议。会议应参加表决的董事 9 名，实际参加表决的董事 9 名（其中以通讯表决方式出席会议的董事 4 名）。会议由董事长黄河先生主持召开， 高级管理人员列席会议。会议召开符合法律法规、《公司法》及《公司章程》的规定， 会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于调整第三届董事会审计委员会成员的议案》 证券代码：601089 证券简称：福元医药 公告编号：临2025-079 北京福元医药股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （二）审议通过《关于子公司投资建设"高精尖药品数智产业化项目"的议案》 根据公司全资子公司福元药业有限公司（以下简称"福元药业"）经营发展需要， 会议同意福元药业投资建设"高精尖药品数智产业化项目"，项目投 ...

2025 年第二次临时股东会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 法律意见书 浙江天册律师事务所 关于 北京福元医药股份有限公司 关于北京福元医药股份有限公司 2025 年第二次临时股东会的 法律意见书 编号：TCYJS2025H1836 号 致：北京福元医药股份有限公司 浙江天册律师事务所（以下简称"本所"）接受北京福元医药股份有限公司 （以下简称"福元医药"或"公司"）的委托，指派本所律师参加公司 2025 年第 二次临时股东会，并根据《中华人民共和国证券法》（以下简称"《证券法》"）、 《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司股东会》 （以下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要求出 具本法律意见书。 在本法律意见书中，本所律师仅对本次股东会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及表决结果的合法有效性发表意见，不对会议所 审议的议案内容和该等议案中所表述的事实或数据的真实性和准确性发表意见。 本 ...

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Ezetimibe and Atorvastatin Calcium Tablets (I), which will enhance the company's product line and market competitiveness [1][5]. Drug Registration Certificate Details - The drug registration certificate (Certificate No. 2025S03344) was issued by the National Medical Products Administration (NMPA) for Ezetimibe and Atorvastatin Calcium Tablets (I), which contains 10mg of Ezetimibe and 10mg of Atorvastatin Calcium per tablet [1][2]. - The drug is indicated for hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) and was first approved by the FDA in May 2013 [1][2]. R&D Investment - The total R&D investment for this drug has reached RMB 5.0458 million (unaudited) as of the date of the announcement [3]. Market Status of Similar Drugs - According to data from Minai Network, the sales revenue of Ezetimibe and Atorvastatin Calcium Tablets in China for the first half of 2025 was approximately RMB 8.64 million, with sales from urban public hospitals and county-level public hospitals accounting for RMB 6.74 million [4]. - Sales from urban community centers and township health clinics were RMB 1.77 million, while urban pharmacies and online pharmacies contributed RMB 0.13 million [4].

证券代码：601089 证券简称：福元医药 公告编号：临 2025-076 药品名称 药品通用名称：依折麦布阿托伐他汀钙片（Ⅰ） 英文名/拉丁名：Ezetimibe and Atorvastatin Calcium Tablets（Ⅰ） 剂型 片剂 注册分类 化学药品4类 规格 每片含依折麦布10mg与阿托伐他汀钙10mg（按 C₃₃H₃₅FN₂O₅计） 药品批准文号 国药准字H20255884 药品注册标准编号 YBH27552025 一、药品注册证书主要内容 | 处方药/非处方药 | 处方药 | | --- | --- | | 申请事项 | 药品注册（境内生产） | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规 批准注册，发给药品注册证书。质量标准、说 | | | 定，经审查，本品符合药品注册的有关要求， | | | 明书、标签及生产工艺照所附执行。药品生产 | | | 企业应当符合药品生产质量管理规范要求方可 | | | 生产销售。 | | 上市许可持有人 | 北京福元医药股份有限公司 | | 生产企业 | 北京福元医药股份有限公司 | 二、药品相关信息 依折麦布阿托伐他汀钙片（Ⅰ）由 O ...

Core Viewpoint - The approval of Ezetimibe Atorvastatin Calcium Tablets (I) by the National Medical Products Administration marks a significant milestone for the company, allowing it to produce and market the drug in China for treating high cholesterol and homozygous familial hypercholesterolemia (HoFH) [1] Company Summary - The company, Fuyuan Pharmaceutical (601089.SH), has received the drug registration certificate for Ezetimibe Atorvastatin Calcium Tablets (I) from the National Medical Products Administration [1] - The drug contains 10mg of Ezetimibe and 10mg of Atorvastatin Calcium per tablet [1] - The drug was developed by Organon and was first approved by the FDA in May 2013 [1] - The approval for the drug's market entry in China was granted in September 2023 [1] Industry Summary - Ezetimibe Atorvastatin Calcium Tablets (I) are indicated for the treatment of high cholesterol and homozygous familial hypercholesterolemia (HoFH) [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the production of Ezetimibe and Atorvastatin Calcium Tablets (I), marking a significant milestone for its product portfolio in the cholesterol management market [1] Company Summary - The approved drug, Ezetimibe and Atorvastatin Calcium Tablets (I), was developed by Organon and was first approved by the FDA in May 2013 [1] - The drug is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [1] - The company received the acceptance notice for the application on January 8, 2025, and has recently obtained the drug registration certificate from the National Medical Products Administration [1] - The issuance of the drug registration certificate is considered equivalent to passing the consistency evaluation according to national policy regulations [1] Industry Summary - The approval of Ezetimibe and Atorvastatin Calcium Tablets (I) in China is part of a broader trend in the pharmaceutical industry focusing on cholesterol-lowering medications [1] - The market for cholesterol management drugs is expected to grow, driven by increasing awareness of cardiovascular diseases and the need for effective treatment options [1]